摘要
目的:提高膀胱癌术后病人的生存率和生存质量。方法:采用术后放疗加顺铂灌注联合治疗83例为实验组,术后单纯放疗77例为对照组,进行疗效观察比较。结果:随访1、3、5年,总生存率及无瘤生存率实验组分别为97.6％(81/83)、82.7％(67/81)、89.6％(60/67)和94.0％(78/83)、89.7％(70/78)、84.3％(59/70);对照组分别为92.2％(71/77)、84.5％(60/71)、75.0％(45/60)和88.3％(68/77)、77.9％(53/68)、73.6％(39/53).两组复发和转移情况,实验组分别为15.7％(13/83)和8.4％(7/83);对照组分别为23.4％(18/77)和18.2％(14/77),经统计学处理,差异具有显著性(P<0.05)。结论:通过160例术后患者分为两组进行随机对照试验,实验组优于对照组,显示出术后放疗联合顺铂灌注对膀胱癌术后综合治疗的良好效果。
Purpose: In order to improve the treatment results of post-operative irradiation, a comparison is made between radiotherapy only and radiotherapy plus cisplatin infusion in the bladder after surgery for carcinoma of the bladder. Methods: 83 patients with carcinoma of the bladder were treated by radiotherapy plus cisplatin infusion of the bladder after surgery as study group and another 77 patients were treated with radiotherapy only as control group. Results: The 1-, 3- and 5 -year survival rates and no evidence of disease rates in study group were 97. 6% (81/83), 82. 7 % (67/81), 89. 6% (60/ 67) and 94.0%(78/83), 89. 7% (70/78) , 84. 3%(59 /70); they were 92. 2% (71/77), 84. 5% (60/71), 75.0% (45/60) and 88. 3% (68/77), 77.9% (53/68), 73. 6% (39/53) in the control group, respectively. The relapse and metastasis rates were 15.7% (13/83) and 8.4% (7/83) in study group;; 23.4% (18/77) and 18.2% (14/77) in the control group(P <0. 05). Conclusions: The effects of the study group is significantly better than the control group. This reveals that radiotherapy plus cisplatin bladder infusion has better results for carcinoma of bladder after operation.
出处
《中国癌症杂志》
CAS
CSCD
2002年第6期548-550,共3页
China Oncology
关键词
膀胱癌
术后放疗
顺铂灌注
治疗
bladder carcinoma
radiotherapy
cisplatin infusion
